Celularity, Inc. (CELU)
|Net Income (ttm)||-355.13M|
|Day's Range||6.81 - 7.15|
|52-Week Range||6.00 - 13.40|
|Est. Earnings Date||n/a|
Celularity Inc., a clinical stage biotechnology company, develops placental-derived allogeneic cell therapies. The company offers genetically modified and unmodified NK cells; engineered T cells, including CAR-T cells; and mesenchymal-like adherent stromal cells targeting indications across cancer, immunologic, infectious, and degenerative diseases. It also offers cell therapy candidates in pre-clinical and clinical development, as well as placental-derived products for surgical use. The company was founded in 2016 and is based in Florham Park,... [Read more...]
In 2020, Celularity's revenue was $14.28 million, a decrease of -32.48% compared to the previous year's $21.15 million. Losses were -$208.23 million, -1.72% less than in 2019.Financial Statements
Renowned clinician, scientist and proven executive leader in biotechnology and healthcare with more than 25 years' experience developing life-changing cellular medicines Renowned clinician, scientist an...
FLORHAM PARK, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (“Celularity”) (Nasdaq:CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies...
Imugene and Celularity Announce an Exclusive Strategic Partnership to Develop a Novel Oncolytic Virus - Allogeneic CA...
SYDNEY, Australia and FLORHAM PARK, N.J., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Imugene Ltd (“Imugene”) (ASX: IMU), a clinical stage immuno-oncology company and Celularity Inc. (“Celularity”) (Nasdaq: CELU)...
The SPAC closed its merger with clinical-stage biotech Celularity.
GXGX's merger announcement is causing the stock to soar this afternoon. The SPAC is merging with biotech play Celularity.
Common stock of the merged company, Celularity, Inc., to commence trading on the Nasdaq Capital Market under the ticker symbol “CELU” on July 19, 2021
NEW YORK, May 14, 2021 /PRNewswire/ -- GX Acquisition Corp. ("GX") (NASDAQ: GXGX), a publicly-traded special purpose acquisition company, announced today that its stockholders have voted to approve an a...
NEW YORK, May 10, 2021 /PRNewswire/ -- GX Acquisition Corp. ("GX") (NASDAQ: GXGX), a publicly-traded special purpose acquisition company, today reaffirmed its intention to support the proposal to amend ...
GX Acquisition Corp. Provides Information Regarding Extension of Deadline to Complete Celularity Business Combination
NEW YORK, April 16, 2021 /PRNewswire/ -- On April 14, 2021, GX Acquisition Corp. ("GX") (NASDAQ: "GXGX"), provided information regarding a proposal to amend GX's amended and restated certificate of inco...